BetterLife Pharma Inc.
No enriched coverage for $BETRF in the last 7 days.
No SEC Form 4 filings for $BETRF in the last 30 days.
See all $BETRF insider activity →BetterLife Pharma (CSE:BETR, OTCQB:BETRF, FSE:NPAU) appointed Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board. Dr. Lipton is a renowned neurology expert and has authored over 1,200 publications. The company granted him options for 500,000 shares. BetterLife is developing BETR-001 for chronic headache and migraine treatment.
BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has formed a Scientific Advisory Board, appointing Professor Peter Goadsby as Co-Chair to guide the development of BETR-001 for chronic cluster headache and chronic migraine. Goadsby is recognized for his research on CGRP, a key driver of migraine. The company granted him stock options for 500,000 shares. BETR-001 is an investigational product not yet approved by any regulatory authority.
BetterLife Pharma (BETR) faces a lawsuit from director Steven Sangha seeking conversion of a debenture into 33,333,333 shares and warrants. The company plans to contest the claim, which could impact dilution and market value.
Recent BETRF coverage spans corporate actions and financial news.
BetterLife Pharma (CSE:BETR, OTCQB:BETRF, FSE:NPAU) appointed Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board. Dr. Lipton is a renowned neurology expert and has authored over 1,200 publications. The company granted him options for 500,000 shares. BetterLife is developing BETR-001 for chronic headache and migraine treatment.
BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has formed a Scientific Advisory Board, appointing Professor Peter Goadsby as Co-Chair to guide the development of BETR-001 for chronic cluster headache and chronic migraine. Goadsby is recognized for his research on CGRP, a key driver of migraine. The company granted him stock options for 500,000 shares. BETR-001 is an investigational product not yet approved by any regulatory authority.
BetterLife Pharma (BETR) faces a lawsuit from director Steven Sangha seeking conversion of a debenture into 33,333,333 shares and warrants. The company plans to contest the claim, which could impact dilution and market value.
BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.
BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.
AlphAI scores every news story that mentions BETRF with an AI model for sentiment and relevance, and aggregates insider trades from BetterLife Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BetterLife Pharma (CSE:BETR, OTCQB:BETRF, FSE:NPAU) appointed Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board. Dr. Lipton is a renowned neurology expert and has authored over 1,200 publications. The company granted him options for 500,000 shares. BetterLife is developing BETR-001 for chronic headache and migraine treatment.
1 min readBetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has formed a Scientific Advisory Board, appointing Professor Peter Goadsby as Co-Chair to guide the development of BETR-001 for chronic cluster headache and chronic migraine. Goadsby is recognized for his research on CGRP, a key driver of migraine. The company granted him stock options for 500,000 shares. BETR-001 is an investigational product not yet approved by any regulatory authority.
2 min readBetterLife Pharma (BETR) faces a lawsuit from director Steven Sangha seeking conversion of a debenture into 33,333,333 shares and warrants. The company plans to contest the claim, which could impact dilution and market value.
1 min readBetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.
4 min readBetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.
2 min readBetterLife Pharma (CSE: BETR, OTCQB: BETRF, FSE: NPAU) appointed Charles Duncan, PhD, as Director and Chair of the Audit Committee. Dr. Duncan has 30 years of biotechnology and capital markets experience. The company granted him stock options for 500,000 shares, vesting over 24 months, and 125,000 shares, vesting over 3 months. BetterLife focuses on developing BETR-001 for migraine and headache disorders.
2 min readBetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.
2 min read
